Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tg100-115. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG known ✓ | P48736 | 13/20 | 0.97 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 0.97 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.97 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.97 |
| ▸ | MTOR | P42345 | 2/20 | 0.97 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.97 |
| ▸ | PDXK | O00764 | 1/20 | 0.97 |
| ▸ | GAK | O14976 | 1/20 | 0.97 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.97 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.97 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.97 |
| ▸ | STK16 | O75716 | 1/20 | 0.97 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.97 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.97 |
| ▸ | OXSR1 | O95747 | 1/20 | 0.97 |
| ▸ | LATS1 | O95835 | 1/20 | 0.97 |
| ▸ | ABL1 | P00519 | 1/20 | 0.97 |
| ▸ | EGFR | P00533 | 1/20 | 0.97 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.97 |
| ▸ | LCK | P06239 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tg100-115 SCHEMBL29361550 | 0.98 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL29369340 | 0.98 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL29506727 | 0.98 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL360279 | 0.98 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL31238338 | 0.98 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL29411790 | 0.98 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL3539251 | 0.97 | PIK3CG (0.97) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL3539255 | 0.97 | PIK3CG (0.97) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| SCHEMBL13403357 | 0.91 | PIK3CG (0.85) | PIK3CGPIK3CAPIK3CBMTORPIK3CD | |
| Tg100-115 SCHEMBL3743017 | 0.90 | PIK3CG (0.82) | PIK3CGPIK3CAPIK3CBMTORPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2039683-B1 | Vasculostatic agents and methods of use thereof | TARGEGEN INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC. | 2010-11-04 | — | — | US | disclosed |
| US-7691858-B2 | Kinase inhibitors and methods of use thereof | TARGEGEN, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-2039683-A2 | Vasculostatic agents and methods of use thereof | Targegen, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1549614-A4 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007127366-A2 | KINASE INHIBITORS AND METHODS OF USE THEREOF | TARGEGEN, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070259876-A1 | Kinase inhibitors and methods of use thereof | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2007-09-06 | — | — | US | disclosed |
| US-7208493-B2 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050282814-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| EP-1549614-A2 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | Targegen, Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040167198-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004030635-A2 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259876-A1 | Kinase inhibitors and methods of use thereof | ROCK1, ADCK1, MAP3K20 | PIK3CG 180/4885PIK3CD 245/4885PIK3CA 163/4885 |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | RBP1, RBP4, VCAM1 | PIK3CG 2378/4885PIK3CD 3513/4885PIK3CA 3097/4885 |
| US-20050282814-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | PIK3CG 2378/4885PIK3CD 3513/4885PIK3CA 3097/4885 |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | PIK3CG 2378/4885PIK3CD 3513/4885PIK3CA 3097/4885 |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | RBP1, RBP4, VCAM1 | PIK3CG 2378/4885PIK3CD 3513/4885PIK3CA 3097/4885 |
| US-20040167198-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | PIK3CG 2378/4885PIK3CD 3513/4885PIK3CA 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.